“This was a three-dose vaccine,” said Paul Offit, a member of the FDA committee and director of the Vaccine Education Center at Children’s Hospital of Philadelphia. “I think this worked out for the best.”

“The plan to have two doses be given while awaiting data on a third dose never made sense to me,” Leana Wen, an emergency physician and public health professor at George Washington University told Axios. “You can’t just approve something and say it’s safe and effective if you haven’t seen the data.”